Investigator to Receive $1.5 Million Grant from a ALS Association to Help …

July 3, 2015 - als








<!– imageTag: –>
<!– imageTagafter: and imageUrl: http://als.esy.es/wp-content/plugins/RSSPoster_PRO/cache/1e518_199512LOGO –>











TripAdvisor Logo. (PRNewsFoto/TripAdvisor)
Neuraltus Pharmaceuticals Logo
Facebook
Twitter
Pinterest








  • <!– assetXML:
    left
    0
    Neuraltus Pharmaceuticals Logo
    http://photos.prnewswire.com/prnfull/20150417/199512LOGO
    http://als.esy.es/wp-content/plugins/RSSPoster_PRO/cache/e7d47_199512LOGO
    http://photos.prnewswire.com/prnthumb/20150417/199512LOGO
    http://photos.prnewswire.com/prnh/20150417/199512LOGO
    http://photos.prnewswire.com/prnvar/20150417/199512LOGO

    and http://photos.prnewswire.com/prnh/20150417/199512LOGO –>


    <!– ItemAssetXML:
    left
    0
    Neuraltus Pharmaceuticals Logo
    http://photos.prnewswire.com/prnfull/20150417/199512LOGO
    http://als.esy.es/wp-content/plugins/RSSPoster_PRO/cache/e7d47_199512LOGO
    http://photos.prnewswire.com/prnthumb/20150417/199512LOGO
    http://photos.prnewswire.com/prnh/20150417/199512LOGO
    http://photos.prnewswire.com/prnvar/20150417/199512LOGO

    and http://als.esy.es/wp-content/plugins/RSSPoster_PRO/cache/e7d47_199512LOGO –>
    Neuraltus Pharmaceuticals Logo









PALO ALTO, Calif., July 1, 2015 /PRNewswire/ — Neuraltus Pharmaceuticals, Inc., a privately-held biopharmaceutical association focused on a growth of groundbreaking drugs to yield neurodegenerative diseases such as amyotrophic parallel sclerosis (ALS), announced now that Robert G. Miller, M.D., Director of a Forbes Norris MDA/ALS Research Center during Sutter Health’s California Pacific Medical Center in San Francisco, has been awarded a extend from The ALS Association for $1.5 million to assistance account a Phase 2 clinical investigate of a company’s investigational therapy for ALS, NP001. Inflammation is suspicion to be a contributing means to ALS illness progression, and NP001 is believed to revoke neuroinflammation by a law of macrophage white blood cells within a executive shaken system. The Phase 2 investigate is dictated to assistance endorse a intensity clinical advantages seen in a prior investigate of NP001, a formula from that were published in a April 2015 emanate of Neurology: Neuroimmunology Neuroinflammation, an executive biography of a American Academy of Neurology. Approximately 400,000 people worldwide are vicious with ALS, also famous as Lou Gehrig’s disease, a on-going and deadly neurodegenerative illness that affects engine neurons in a mind and a spinal cord.i 

“ALS is a deadly condition with singular diagnosis options,” pronounced Dr. Miller. “Clinical investigate of earnest investigational drugs, like NP001, is critically vicious as we continue to learn some-more about this harmful disease. This Phase 2 investigate is approaching to yield profitable insights, not usually about NP001, though also on a purpose of inflammation in illness course and a biomarkers identified by Neuraltus in a prior study.” 

The Phase 2 study, that is approaching to start before a finish of a year, will be designed to endorse a intensity impact of NP001 on dual inflammation biomarkers: interleukin-18 (IL-18) and a participation of lipopolysaccharide (LPS) in a blood. The investigate will concentration on patients who have had ALS symptoms for reduction than 3 years with a vicious ability (breathing test) larger than 65 percent. More specific sum per a Phase 2 investigate of NP001 will be disclosed during a time of hearing initiation. The $1.5 million grant, awarded by The ALS Association, will be total with approximately $1.2 million in appropriation and support contributed by Neuraltus.

“The some-more we can learn from earnest research, like that being conducted by Dr. Miller and a Neuraltus team, a some-more discernment we have into a physiological form of ALS,” pronounced Lucie Bruijn, Ph.D. M.B.A, Chief Scientist, The ALS Association. “Awarding grants to account investigate like a Phase 2 investigate of NP001 is undeniably vicious in a office of probable diagnosis options for ALS patients.”

“We conclude a extend support from The ALS Association to assistance us allege a clinical growth of NP001 as a intensity diagnosis for patients with ALS,” pronounced Rich Casey, Neuraltus Pharmaceuticals’ Chief Executive Officer. “We demeanour brazen to operative with Dr. Miller, a ALS village and The ALS Association on this Phase 2 investigate as we work to allege NP001 as fast as probable toward a pivotal clinical trial.”

About Amyotrophic Lateral Sclerosis

Amyotrophic parallel sclerosis (ALS, or Lou Gehrig’s disease) is a singular and deadly neurodegenerative illness characterized by a lapse of engine neurons in a spinal cord and brain.

There are approximately 400,000 ALS patients worldwide, including approximately 30,000 patients in the United States and 50,000 patients in Europe. Most patients and physicians news usually medium negligence of ALS course from existent diagnosis for ALS, underscoring a need for new and effective drug therapy.

About NP001

The means of ALS is now unknown, though there is augmenting justification that implicates neuroinflammation with a course of a disease. It is believed that in people with ALS, there are increasing levels of inflammatory (activated) macrophage white blood cells ensuing in a recover of factors in a executive shaken complement that lead to repairs of engine neurons. NP001, a regulator of macrophage activation, exerts a outcome by converting these activated inflammatory macrophages behind to their normal state.

About The ALS Association

The ALS Association is a usually inhabitant non-profit classification fighting Lou Gehrig’s illness on each front. By heading a approach in tellurian research, providing assistance for people with ALS by a national network of chapters, coordinating multidisciplinary caring by authorized clinical caring centers, and fostering supervision partnerships, The Association builds wish and enhances peculiarity of life while aggressively acid for new treatments and a cure. For some-more information about The ALS Association, revisit a website during www.alsa.org.

About Neuraltus Pharmaceuticals, Inc.

Neuraltus Pharmaceuticals, Inc. is a privately-held biopharmaceutical association dedicated to building and commercializing high-impact therapeutics that residence vicious unmet needs for patients and physicians, essentially in a diagnosis of neurodegenerative diseases. Neuraltus recognizes that ALS is a harmful condition, with usually one authorized therapy, and is focused on building and bringing a investigational treatments to marketplace as fast as possible. The Company is collaborating with tellurian ALS specialists and seeking submit from studious advocacy organizations to assistance surprise a clinical growth trail and improved know a needs of people influenced by a disease. In further to NP001, Neuraltus also has a pre-clinical program, NP003, for a diagnosis of lysosomal storage disorders such as Fabry’s illness and Gaucher’s disease.

For some-more information on Neuraltus, greatfully revisit www.neuraltus.com.

i What is ALS? The ALS Association. Viewed on June 12, 2015. Accessed here: http://www.alsa.org/about-als/what-is-als.html?referrer=https://www.google.com/.

Contact: Edie DeVine, GCI Health
Office: +1 (209) 814-9564 

Logo – http://photos.prnewswire.com/prnh/20150417/199512LOGO

SOURCE Neuraltus Pharmaceuticals, Inc.

RELATED LINKS
http://www.neuraltus.com

source ⦿ http://www.prnewswire.com/news-releases/investigator-to-receive-15-million-grant-from-the-als-association-to-help-fund-confirmatory-phase-2-study-of-neuraltus-pharmaceuticals-np001-300107339.html

› tags: als /